RIQAS Standard Report

Home - Laboratory - Page 4

RIQAS Standard Report

There are a variety of RIQAS reports designed to enable quick and easy identification of any trends or test system issues. The standard quantitative report is provided in a user-friendly, one page per parameter format allowing a visual, at-a-glance assessment of performance. The standard quantitative report is split into several easy to interpret subsections each designed to save valuable laboratory time.

You can explore each of the report sections using the table below. Don’t forget, to enlarge the image, simply click on it.

RIQAS EQA Reports

RIQAS Reports Features

Performance data is presented in a simple one page format for each analyte. Each one page report comprises seven sub-reports providing a statistical and graphical representation of laboratory performance.

(Click to enlarge)

The text section provides a statistical breakdown of results by all methods, your method and instrument group. The Mean, CV% and Uncertainty or Measurement is presented for each comparison group.

Your laboratory’s result is compared to the Mean for Comparison (usually the instrument group Mean). Also included are the RIQAS performance indicators; SDI, Target Score and %Deviation.

Acceptable performance criteria:

  • SDI <2
  • Target Score >50
  • %Deviation

The defined acceptable limits default to the RIQAS TDPA values but may be based on CLIA, biological variation or country specific limits.

Performance goals based on Biological Variation are also stated within the text section for information purposes.

 

(Click to enlarge)

The histogram chart provides an overview of how your laboratory’s result compares to the all method group, your method group and your instrument group. Your result is represented by a black triangle; the closer to the centre the better.

The chart is intended to provide a quick visualisation of performance compared to other method groups and can be used to identify any potential bias.

(Click to enlarge)

The Levey-Jennings chart plots the last 20 SDI’s and is extremely useful for monitoring EQA performance over time, allowing quick and easy identification of any trends or bias. The chart is colour coded making interpretation simple and easy; results that fall in the white area are excellent and those in the red area unacceptable.

(Click to enlarge)

The Target Score (TS) chart is a unique chart which displays your laboratory’s last 20 target scores delivering an instant, visual indication of performance. The TS chart is conveniently colour coded for even easier performance assessment, a TS >50 is acceptable. The TS is a numerical index relating your %Deviation from the mean to a Target Deviation for Performance Assessment (TDPA).

(Click to enlarge)

The %Deviation by sample chart displays the %Deviation for the last 20 EQA samples enabling identification of trends and shifts in performance. Similar to the other charts on the RIQAS report, the %Deviation by sample chart is shaded to indicate the limit of acceptable performance. A black dot within the white section of the chart will represent results with a %Deviation within your acceptable limits of performance; a black dot within the red section of the chart will represent results with a %Deviation outside your acceptable limits of performance. %Deviations are not influenced by the performance of your peers, as seen with the standard deviation index (SDI) and therefore is a better indicator of individual performance.

(Click to enlarge)

The %Deviation by concentration chart enables easy detection of possible concentration related biases. Unlike the other charts provided on the report, the %Deviation by concentration chart displays the concentration range of the previous 20 samples along the bottom of the chart.

Using this scale along with the percentage deviation, you are provided with a rapid assessment of your %Deviation in relation to the concentration of the:

• Current sample (represented by a square)
• Your 19 previous results (represented by circles)

This chart provides an easy interpretation of potential positive or negative biases at high or low concentrations, or whether a particular sample is a random outlier.

(Click to enlarge)

The Multi Method Stat Section provides you with an easy way of assessing the performance of the other methods used to analyse the parameter. This is useful when your laboratory plans to change the analytical method used for the parameter.

(Click to enlarge)

Located at the back of the standard quantitative report, our quick reference summary page details the performance for each registered parameter in the programme.

Within the performance column, RIQAS provides an effortless method of assessing the performance of each parameter within the sample distribution. When a red triangle appears next to the parameter, this indicates that all performance indicators (SDI, TS and %DEV) have exceeded the performance criteria.

The performance indicator limits for each parameter are exceeded when your result produces:
• An SDI greater than +/- 2 standard deviations.
• A Target Score less than 50 (only when Target Scoring is available)
• A %Deviation greater than your set acceptable limits of performance.

(Click to enlarge)

A summary CSV file is available on request to all participating laboratories. The report provides a summary of all statistics, acceptable limits and performance indicators as a .csv file for each sample in the cycle.

A retrospective statistics summary is also available, four weeks after the final submission date for parameters where a result was not submitted on time.


Acusera Internal Quality Control Analyte List

Quality Control is our passion; we believe in producing high quality material that can help streamline procedures, whilst saving time and money for laboratories of all sizes and budgets. With an extensive product offering comprising third party controls and calibrators, interlaboratory data management, external quality assessment, and calibration verification, you can count on Randox to deliver trustworthy results time and time again. Just ask one of our 60,000 users worldwide.

Our Acusera Internal Quality Control A – Z analyte list highlights how comprehensive our Acusera product portfolio is. Search through the list to see if we have the analyte you require.

Acusera Parameter List

#

5-HIAA
7-amino flunitrazepam
11 dhTXB₂
17-OH-progesterone
17β Clostebol
1-25-(OH₂)-Vitamin D
25-OH-Vitamin D

A

α-1-Acid Glycoprotein
α-1-Antitrypsin
α-1-Globulin (Electrophoresis)
α-2-Globulin (Electrophoresis)
α-2-Macroglobulin
α-Fetoprotein (AFP)
α-HBDH
Acetaminophen
Acid Phosphatase (Non-Prostatic)
Acid Phosphatase (Prostatic)
Acid Phosphatase (Total)
ACTH
Activated Partial Thromboplastin Time (APTT)
Adiponectin
AHD
Albumin
Albumin (Electrophoresis)
Aldolase
Aldosterone
Alkaline Phosphatase (ALP)
ALT (GPT)
Amikacin
Ammonia
AMOZ
Amphetamine
Amylase
Amylase (Pancreatic)
Androstenedione

Anti-Streptolysin (ASO)
Anti-Thyroglobulin (Anti-TG)
Anti-Thyroperoxidase (Anti-TPO)
Anti-Thrombin III (AT III)
AOZ
Apolipoprotein A-I
Apolipoprotein A-II
Apolipoprotein B
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein E
AST (GOT)

B

β-Globulin (Electrophoresis)
β-2-Microglobulin
β-Agonists (Clenbuterol)
Barbiturates
BASO-X
BASO-Y
Basophils (BASO)
Basophils % (% BASO)
Bath Salts 1
Bath Salts 2
Benzodiazepines 1 + 2
Benzoylecgonine (Cocaine)
Benzylpiperazines
Bicarbonate
Bile Acids
Bilirubin (Direct)
Bilirubin (Total)
Blood
BNP
Boldenone
Brain Derived Neurotropic Factor (BDNF)
Buprenorphine

C

C-Peptide
CA 15-3
CA 19-9
CA 27-29
CA 72-4
CA 125
Caffeine
Calcitonin
Calcium
Cannabinoids
Carbamazepine
CEA
Ceftiofur
Ceruloplasmin
Chloral Hydrate Metabolite
Chloramphenicol
Chloride
Cholesterol (HDL)
Cholesterol (LDL)
Cholesterol (Total)
Cholinesterase
CK-MB
CK (Total)
Complement C3
Complement C4
Copper
Corticosteroids
Cortisol
CRP
Creatinine
Cyclosporine
CYFRA 21
Cystatin C

D

D-3-Hydroxybutyrate
D-dimer
Dextromethorphan
DHEA-Sulphate

DIFF-X
DIFF-Y
Digoxin
Dopamine

E

E-Selectin (E-SEL)
EDDP
Eosinophils (EOS)
% Eosinophils (% EOS)
Epidermal Growth Factor (EGF)
Epinephrine
Escitalopram
Estriol
Ethanol
Ethinylestradiol
Ethosuximide
Ethyl Glucuronide

F

Factor II
Factor V
Factor VII
Factor VIII
Factor IX
Factor X
Factor XI
Factor XII
Fatty Acid Binding Protein (FABP)
Fentanyl
Ferritin
Fibrinogen
Fluoxetine
Folate
Fructosamine
FSC-X
FSH

G

G-6-PDH
γ-Globulin (Electrophoresis)
γGT
Gastrin
Gentamicin
Gestagens (Generic)
GLDH
Glial Fibrillary Acidic Protein (GFAP)
Glucose
Glutamate
Glutamine
Glutathione Peroxidase (Ransel)
Glutathione Reductase
Glycerol
GM-CSF
Growth Hormone (GH)

H

H-FABP
Haematocrit (HCT)
Haemoglobin (HGB)
Haemoglobin A2 (HbA2)
Haemoglobin F (HbF)
Haemoglobin S (HbS)
Haemoglobin (Total)
Haemopioetic Progenitor Cell (HPC)
Haloperidol
Haptoglobin
HbA1c
hCG
Free β-hCG
Total β-hCG
Homocysteine
hsCRP

I

Ibuprofen

IMIDC
IMIRF
Immature Granulocytes (IG)
% Immature Granulocytes (% IG)
Immature Myeloid Information (IMI)
Immature Platelet Fraction (IPF)
Immunoglobulin A (IgA)
High Sensitivity Immunoglobulin A (hsIgA)
Immunoglobulin E (IgE)
Immunoglobulin G (IgG)
High Sensitivity Immunoglobulin G (hsIgG)
Immunoglobulin M (IgM)
High Sensitivity Immunoglobulin M (hsIgM)
Inhibin A
Insulin
Insulin Like Growth Factor-1 (IGF-I)
Intercellular Adhesion Molecule-I (ICAM-I)
Interferon-γ (IFN-γ)
Interleukin-Ia (IL-la)
Interleukin-1β (IL-1β)
Interleukin-2 (IL-2)
Interleukin-4 (IL-4)
Interleukin-5 (IL-5)
Interleukin-6 (IL-6)
Interleukin-8 (IL-8)
Interleukin-10 (IL-10)
Interleukin-15 (IL-15)
Iron
Iron (TIBC)
Iron (UIBC)

K

Kappa Light Chain
Kappa Light Chain (Free)
Ketamine Metabolite
Ketones

L

L-Selectin (L-SEL)
Lactate
Lactate Dehydrogenase (LDH)
Lambda Light Chain
Lambda Light Chain (Free)
LAP
Leptin
Leukocytes
Lipase
Lipoprotein (a)
Lithium
Luteinising Hormone (LH)
Lymphocytes (LYMPH)
% Lymphocytes (% LYMPH)
Lysergic Acid Diethylamide (LSD)

M

Magnesium
Matrix Metalloproteinase-9 (MMP-9)
Mean Corpuscular Haemoglobin (MCH)
Mean Corpuscular Haemoglobin
Concentration (MCHC)
Mean Corpuscular Volume (MCV)
Mean Platelet Volume (MPV)
Meprobamate
Meperidine
Mescaline
Metanephrine
Methadone
Methandriol
Methamphetamine
Methaqualone
Methotrexate
Methylphenidate

Methyltestosterone
MDMA
Microalbumin
Macrophage Inflammatory Protein-1α (MIP-1α)
Monocytes (MONO)
Monocytes % (% MONO)
Monocyte Chemoattractant Protein-1 (MCP-1)
Morphine (Opiates)
Myoglobin

N

Nandrolone
NEFA
Neuron-Specific Enolase (NSE)
Neutrophils (NEUT)
Neutrophils % (% NEUT)
Neutrophil Gelatinase-associated Lipocalin (NGAL)
Nitrite
Norepinephrine
Normetanephrine
NT-proBNP
Nucleated Red Blood Cells (NRBC)
Nucleated Red Blood Cells % (% NRBC)
Nucleated Red Blood Cells X (NRBC-X)
Nucleated Red Blood Cells Y (NRBC-Y)

O

Oestradiol
Opiates
Osmolality
Osteocalcin
Oxalate
Oxazepam
Oxycodone (I+II)

P

P-Selectin (P-SEL)
Paracetamol
PAPP-A
pCO₂
pH
Phencyclidine
Phenobarbital
Phenylpiperazines
Phenytoin
Phosphate (Inorganic)
Plasminogen
Plasminogen Activator Inhibitor
Platelet Distribution Width (PDW)
Platelet Large Cell Ratio (P-LCR)
Plateletcrit (PCT)
Platelet (PLT)
Platelet Optical Count (PLT-O)
pO₂
Potassium
Prealbumin
Primidone
Procalcitonin
Progesterone
Prolactin
Propoxyphene
Protein C
Protein S
Protein (Total)
Prothrombin Time (PT)
PSA (Total)
PSA (Free)
PTH (Intact)

Q

Quinolones (Generic)

R

Ractopamine
Red Blood Cells (RBC)
Red Blood Cells Optical Count (RBC-O)
Red Blood Cell X (RBC-X)
Red Blood Cell Y (RBC-Y)
Red Blood Cell Distribution Width CV
(RDW-CV)
Red Blood Cell Distribution Width SD (RDW-SD)
Renin
Resistin
Retinol Binding Protein (RBP)
Rheumatoid Factor (RF)

S

Salicylate
Salicyluric Acid
Salvinorin
Secobarbital
Semicarbazine (SEM)
Sertraline
Sex Hormone Binding Globulin (SHBG)
sLDL
Sodium
Soluble IL-2 Receptor α (sIL-2Rα)
Soluble IL-6 Receptor (sIL-6R)
Soluble Tumour Necrosis Factor Receptor 1 (sTNFR I)
Soluble Tumour Necrosis Factor Receptor 11 (sTNFR I1)
Specific Gravity
Stanozolol
Stilbenes
Streptomycin
Superoxide Dismutase (Ransod)
Synthetic Cannabinoids (1 to 4)

T

T Uptake
T3 (Free)
T4 (Free)
T3 (Total)
T4 (Total)
Testosterone
Testosterone (Free)
Tetracyclines (Generic)
Theophylline
Thiamphenicol
Thrombin Time (TT)
Thrombomodulin (TM)
Thyroglobulin
Tobramycin
Total Antioxidant Status (TAS)
Tramadol
Transferrin
Trazadone
Trenbolone
Tricyclic Antidepressants
Triglycerides
Trimethoprim
Troponin I
Troponin T
TSH
Tumour Necrosis Factor α (TNFα)
Tylosin

U

Unconjugated Estriol
Urea
Uric Acid (Urate)
Urobilinogen

V

Valproic acid
Vancomycin
Vanillylmandelic Acid (VMA)
Vascular Cell Adhesion Molecule-1 (VCAM-1)
Vascular Endothelial Growth Factor (VEGF)
Vitamin B₁₂

W

White Blood Cells (WBC)
White Blood Cells Differential (WBC-D)

Z

Zaleplon
Zeronal
Zinc
Zolpidem
Zopiclone


Get your teeth into a Randox commutable control this Halloween

Get your teeth into a Randox commutable control this Halloween

It is that time of year again – when people dress up, children trick-or-treat and many a scary story is told in households around the world. An age-old tradition celebrated globally by millions of people – it can only be Halloween.

Last year Randox QC brought you the truly scary story about a laboratory who chose not to use a third party control, but eventually “treated their laboratory to a true third party control”. This year, we have another scary story for you about a lab manager in Transylvania, Dr. Acula.

It was a normal, busy day in the lab for Dr. Acula. That was until it was time to change reagent batch, after changing batch of reagent Dr. Acula was shocked to find his QC results had shifted by over 20%.  This left Dr. Acula very frustrated, having to spend precious time troubleshooting and reassigning QC targets. After troubleshooting showed no apparent root cause, Dr. Acula searched the internet for an answer finally stumbling upon an educational guide from Randox Quality Control on commutability and its many benefits to the lab.

Grinning from ear-to-ear with excitement, Dr. Acula began to read the guide in the hope of finding a solution to his problem – and solutions he found. While reading the guide, Dr. Acula came across a quote from ISO 15189:2012.  It read that laboratories “must use quality control materials that react to the examining system in a manner as close as possible to the patient sample”.

Dr. Acula made a decision to look for a commutable control material that met all of his requirements and he didn’t have to search very far. Randox Quality Control were able to supply Dr. Acula and his laboratory with a QC material to meet all his needs – true third party, excellent stability, consistency and consolidation but most importantly of all commutable controls.  The fact all Randox immunoassay and immunology controls are manufactured from 100% human material appealed to Dr. Acula a lot.  After trialing the Randox control material alongside patient samples and comparing results between reagent batches, Dr. Acula was thrilled with the results.

Labs rely heavily on quality control to detect errors in their test system and to ultimately make critical decisions regarding the accuracy and reliability of patient test results, the use of a control that reacts to the test system in the same manner as a patient sample is therefore essential.

At Randox Quality Control we take quality seriously. All our QC products are manufactured to the highest possible standard ensuring controls of unrivalled quality time and time again. Designed to be commutable, the Acusera range will ensure accurate and reliable instrument performance while simultaneously helping laboratories meet ISO 15189:2012 requirements.

Just ask Dr. Acula, who likes our 100% human controls so much he has started to drink them himself!


Acusera 24.7 Packages Explained

Acusera 24.7 Packages Explained

Packages for Customisation

Acusera 24.7 now boasts even more customisation with the introduction of three distinct packages; Platinum, Gold & Silver.

The Acusera 24.7 software is an interlaboratory data management and peer group reporting package complementing the Acusera range of true third party quality controls. Designed to assist in the management of daily QC activities by providing access to an impressive range of features, including interactive charts and real-time peer group data, Acusera 24.7 Live Online will improve error detection, reduce false rejections, ensure accurate patient results, and help you meet regulatory requirements, such as ISO 15189

The introduction of the new Acusera 24.7 packages ensures a solution to suit laboratories of all sizes and budgets.  All three membership packages give our users access to the world-renowned Acusera 24.7 global peer group, but users now have the flexibility to choose whether they require access to additional features to help revolutionise their QC strategy.

Package Benefits

FEATUREPLATINUMGOLDSILVER
Access to real-time peer group data
FEATUREPLATINUMGOLDSILVER
Multiple levels of user access
Unlimited number of registered users
FEATUREPLATINUMGOLDSILVER
Custom Multi-Rules
Ability to use other manufacturer controls or custom controls
FEATUREPLATINUMGOLDSILVER
Data import via Acusera 24•7 Connect
Manual data entry by panel
Semi automated data entry via EDI
Recording of instrument events
FEATUREPLATINUMGOLDSIGNIFICANCE
Automatic calculation of Mean, SD and %CV
Result History
Automatic calculation of %Bias and Total Error
Automatic calculation of Inter-Precision, Sigma Scores, Uncertainty of Measurement and Expanded Uncertainty
FEATUREPLATINUMGOLDSILVER
Statistical Analysis Report
Peer Group Statistics Report
Exception Report
Statistical Metrics Report
Uncertainty of Measurement Report
FEATUREPLATINUMGOLDSILVER
Levey-Jennings Chart
Histogram Chart
Performance Summary Chart
Multi-Levey Jennings/Histogram Charts
FEATUREPLATINUMGOLDSILVER
Dashboard
Audit Trail
Advisor Tool
Data Review

Learn More About Acusera 24.7 Packages

To learn more about Acusera 24.7 you can visit the webpage, download the brochure or contact us using the form below.


Randox and partners announce opening of £7m Advanced Biomedical Devices laboratory

Randox Laboratories is pleased to announce the opening of a state-of-the-art Advanced Biomedical Engineering Laboratory today, the result of an innovative partnership with some of Northern Ireland’s leading business and education stakeholders.

The strategic collaboration with Invest Northern Ireland, Ulster University and Heartsine Technologies to develop the £7 million laboratory aims to transform the future of healthcare. The lab, which is based at Ulster University, will offer expertise and state of the art equipment to assist companies to develop prototypes for the biomedical, engineering, electronic device and aerospace sectors.

Welcoming the new lab, Dr Peter FitzGerald from Randox Laboratories said: “As one of the UK’s leading life sciences companies, we are delighted to be a partner in this innovative collaboration and to promote Northern Ireland as a global life sciences hub. We believe the greatest improvements to patients’ lives are possible through the continuous development of new technologies.

“This unique laboratory will facilitate that, as it will allow the rapid development of test prototype devices and also assist us to expand our unique range of high-calibre analyser systems.”

Tracey Meharg, Invest NI’s Executive Director of Business Solutions said: “The new Bio Devices Lab is a welcome and exciting development for Northern Ireland’s Health & Life Sciences sector. The facility will open up opportunities for stronger innovation by hosting a suite of equipment which will allow companies to quickly develop prototypes and medical devices for testing.

“It is a great example of how partnerships between government, industry and academia can enhance Northern Ireland as a knowledge economy and boost the credibility and visibility of Northern Ireland as a global leader in connected health.”  

Prof Jim McLaughlin from Ulster University said: Developing technology platforms to help translate our world class science and discovery to a device format as promptly as possible is essential for the very best design and performance.

“In healthcare technology, Ulster University leads the way in the development of new patient monitoring systems, stimulation devices, wearable solutions and diagnostic sensing.

“The lab will enable our researchers to develop the strong leadership and innovation skills so critical to future industry growth, working in collaboration with our industry partners.”

The total investment is £7.4m. Invest NI has offered assistance of £3.7m through a Grant for R&D, with Ulster University contributing £2.9m and £716,000 invested through industry collaborations with Randox Laboratories and Heartsine Technologies. Invest NI’s R&D support is part funded by ERDF under the EU Investment for Growth and Jobs Programme 2014-2020.

Celebrating the opening of the Advanced Biomedical Engineering Laboratory are (from left) Professor Brian Meenan, Ulster University; Tracy Meharg, Invest NI; Professor Jim McLaughlin, Ulster University; and Stuart McGregor, Randox Laboratories


Evidence Series Enquiry

Enquire to find out more about our Biochip powered Evidence Series immunoanalysers 

Committed to meeting customers’ needs

At Randox Quality Control, we strive to meet and exceed customer expectations ensuring high quality products and superior customer service are at the top of our priority list.

How can Randox Quality Control help you?

High Quality QC

The Acusera range of true third party controls boasts an impressive range of benefits ultimately designed to help laboratories reduce costs and time while also ensuring an accurate and reliable test system.

The extended shelf life of our controls allows the same lot of control to be used for a period of up to 2 years keeping costly new lot validation studies to a minimum.  We may also be able to sequester lots on your behalf.

The availability of commutable controls designed to react to the test system in the same manner as a patient sample and controls targeted at clinical decision levels will not only help you to meet ISO 15189:2012 requirements but will effectively challenge instrument performance.

Click here to find out more about our QC range.

Customer support

The Randox global support network are on hand with expert advice to ensure timely, accurate and helpful resolution of any issues or queries you may have. The added benefit of quick delivery of product orders further highlights how we work with and for our customers to provide the best service available.

Customer Reviews

Don’t believe us? Read a few of the reviews we have received from laboratories around the world;

“I would like to thank the Randox team for the excellent service when helping to reserve and manage our IQC orders, lot numbers and stock.” – Chief Biomedical Scientist, London, 2017.

Request your free QC consultation by contacting us today! Get in touch and we can arrange for your laboratory to have a consultation with one of our Randox QC specialists. Alternatively, if you would like to leave us a review you can do so by emailing acusera@randox.com.


RIQAS Frequently Asked Questions (FAQ’s)

  1. How do I register for RIQAS?

Complete the RIQAS method questionnaire and enrolment document for the programmes you wish to participate in. RIQAS will then issue you with a unique laboratory reference number. The enrolment document should be returned to RIQAS before the start of the cycle. These documents can be easily downloaded from the RIQAS website. Simply click on the programme of interest and download the relevant documentation.

  1. What if my current method is not listed in the method questionnaire or enrolment document?

Use the method questionnaire to help you complete the registration of methods section on the enrolment document. If a code is not available for your method/assay please state the details of your method clearly in the appropriate section at the end of the enrolment document.

  1. How do I enter my EQA results?

Participants may conveniently enter their results online via RIQAS.Net.  Alternatively results can be entered via the manual return sheet and submitted by fax or post before the final submission deadline.

  1. How do I know when to submit my EQA results?

Each RIQAS pack will contain a multi-lingual product insert containing instructions for use. The product insert also highlights the recommended date of analysis and more importantly the final date by which the results must reach Randox. The final date for submission of results can also be found on the RIQAS calendar. All results should reach RIQAS before 5pm GMT on the final submission date.

  1. How and when are RIQAS reports issued?

For most programmes reports are available within 72 hours of the final submission date (for RIQAS Serology Programmes, reports are sent via email within 7-10 days of the final submission date).  The reports may be accessed online via RIQAS.Net or alternatively may be sent by email or post. Individual reports may be emailed to up to three addresses.

  1. Can I register multiple instruments for a single EQA programme?

Yes, laboratories can register up to five instruments per programme at no extra cost. Individual reports for each instrument plus a unique multi-instrument report are provided. The multi-instrument report allows for comparative performance assessment of each instrument. Additional sample packs may be ordered as required. 

  1. What is the summary CSV file?

Laboratories can register to receive a CSV file containing a summary of their report statistics, acceptable limits and performance indicators for every sample. The file mirrors the information found on the quantitative report summary page but will also include the calculated SD and SDPA. If you wish to receive a summary CSV file, please indicate this by ticking the box on the enrolment document and include the email addresses to which the reports should be sent.

  1. Is RIQAS accredited to ISO/IEC 17043:2010?

Yes, in 2012 RIQAS celebrated gaining accreditation to ISO/IEC 17043:2010. This standard outlines general requirements for proficiency testing and demonstrates our commitment to quality whilst providing both participants and accrediting bodies with confidence in the schemes operation. Our accreditation to ISO/IEC 17043:2010 highlights the superior quality and excellence of RIQAS. **Please be aware that not all RIQAS programmes are accredited. Programmes marked with a “+” highlight the programmes not accredited.**

9. What if I don’t need all the parameters in a particular EQA programme?

Reduced parameter options are available for selected EQA programmes offering greater flexibility, whilst ensuring suitability for laboratories of all sizes and budgets.

10. How does the group reporting facility work?

The Group Reporting facility enables group co-ordinators to monitor the performance of satellite sites. Each individual laboratory in the group will receive an individual report, the group supervisor will receive a unique instrument group report comparing each laboratory’s performance within the group.

11. Will I receive a certification of participation?

Yes, RIQAS provides certificates as proof of EQA participation and performance for laboratory accreditation purposes. A complimentary certificate of participation for each RIQAS programme is available to participants at the end of each cycle, provided at least 50% of results have been returned. A certificate of performance is also supplied with the end-of-cycle report. Certificates will specify the cycle number, programme name and the LABORATORY / HOSPITAL NAME specified in the enrolment document.

12. Can you offer technical support and advice?

Unrivalled technical support is available through our team of RIQAS scientists and experts who are on hand to offer advice and to help you troubleshoot technical issues relating to our RIQAS programmes.

13. I have found a transcription error on my report. Can I submit the revised result?

Participants are permitted to submit corrected results up to 4 weeks after the final date of the sample. Although a new report will not be issued, results can be viewed on the charts of subsequent reports, showing “C” in place of the sample number. If a result is corrected and resubmitted to RIQAS before the final date for the current sample, it will be entered as a current result.

14. How do I notify a change of method if the cycle is already underway?

It is possible to change your units, method, instrument or reagent classification during a cycle. For participants using RIQAS.Net changes can be made in the method changes section of the data entry menu. Each RIQAS return sheet also has a section for method changes.

15. How do I add extra parameters to my registration?

Extra parameters can be added to a registration via RIQAS.Net using the method changes section on the data entry menu. A list of your registered laboratory reference numbers will appear on screen. Select the laboratory reference number for which you would like to add the assay details and select ‘Add Parameter’. A list of parameters you are not registered for will appear. Select the parameters you wish to add and complete the assay details. Parameters cannot be deleted on RIQAS.Net. If you wish to delete a parameter please contact RIQAS directly on mail@riqas.com.

Do you have a question that needs answered?

Do you have a question that wasn’t answered above? Drop us an email and we will be happy to answer any questions you may have.

 


A week dedicated to unsung heroes! – Medical Laboratory Professionals Week 2017

From April 23rd to April 29th we are celebrating Medical Laboratory Professionals Week! This is a week dedicated to raising awareness for those who work in a laboratory & the hard work that goes unnoticed every day in laboratories around the world.

Have you ever wondered what happens between submitting your patient sample and receiving your results? Have you ever wondered who conducts the detailed laboratory testing for your annual check-up such as cholesterol and glucose levels? Or who analyses these results? The answer, a Medical Laboratory Professional (MLP). MLP’s provide up to 70% of the medical laboratory results for physicians and others to make informed decisions about a patient’s diagnosis and aftercare treatment plan. The work that laboratory professionals do each and every day is integral to providing excellent patient care.  They perform and interpret billions of laboratory tests every year.

Providing accurate and reliable test results is of the utmost importance for laboratory professionals and also for us at Randox. With a passion for Quality Control, and with more than 30 years’ experience developing Laboratory QC for the in vitro diagnostics market, we believe in producing high quality material designed to streamline procedures, whilst reducing costs in laboratories of all sizes and budgets. These qualities have been reflected in our Acusera true third party quality controls, Acusera 24.7 interlaboratory data management software, Acusera Verify Calibration Verification material and RIQAS, the largest international EQA scheme.

Randox Quality Control would like to take this opportunity to thank all the laboratory professionals around the world and especially our own laboratory staff – you truly are the “Unsung Heroes of Healthcare”.


Cutting-edge research and testing centre opens at Randox Science Park

Following the success of the first ever Randox Health Grand National, global health diagnostics company Randox has today announced the official opening of its new central laboratory, Randox Clinical Laboratory Services (RCLS), at the recently acquired Randox Science Park in Antrim, Northern Ireland.

Situated at this new state of the art biohub, the RCLS accredited lab now houses Randox’s latest blood screening equipment – the pioneering Evolution machine.  This new technology enables the labs to conduct a full range of niche and standard research testing, as well as current health testing for the company’s Randox Health division, which offers the world’s most comprehensive full body health analysis.

Research areas at the newly accredited laboratory include but are not exclusive to cancer, fertility, heart, inflammation, stroke and kidney health, both in-house and collaboratively with external organisations.  Current and past collaborations include an Acute Kidney Injury Study with the Royal Victoria Hospital, a Bladder Cancer Study in partnership with Queen’s University Belfast and The Belfast Trust, a Stroke and Brain Injury study with Cambridge University, and key partnerships with a number of major pharmaceutical companies.

A staggering 222 clinical diagnostic tests are currently run routinely with the lab, with more tests pending accreditation in the coming months.

Ann-Marie Jennings, Laboratory Manager for Randox Clinical Laboratory Services, explained that the new facilities will allow RCLS to increase their output and enter new markets;

“Randox Clinical Laboratory Services has been operational for a number of years in our headquarters in Crumlin, near the Belfast International Airport.  Now that we have moved to our new, purpose-built labs in the Randox Science Park, we have the ability to increase the output of both our health testing and our research testing. This involves expanding our team of experienced scientists, working towards further accreditations and furthermore setting up independent labs in Dubai, LA, Holywood and Liverpool in addition to our current labs in Antrim and London.”

Thanks to the new Randox Science Park facilities, the company will now be able to provide an increasingly wide range of testing services to Biotechnology and In Vitro Diagnostic companies, and will deliver to pharmaceutical companies the testing services required to support their drug development projects, in addition to the testing provided to research organisations,

With the ability to conduct an unrivalled range of health testing – haematology, biochemistry and immunoassay – all under one roof, the laboratory offers unparalleled support services to the dynamic and growing healthcare industry.  With a greater understanding of human complexity, pharmaceutical companies are now focusing on developing safer drugs tailored to specific patient groups or sub-groups and the expansion plans in motion at RCLS will help these organisations bring new drugs to market faster.

Ann-Marie continued;

“On our patented Randox Biochip Array Technology we can customize bespoke testing platforms based on the requirements of each drug development project, which can be a challenging process. From initial product development to clinical trial stages there can be a number of barriers and time constraints before drugs are successfully released to the public.  We’re confident that our newly enhanced capabilities will benefit patients suffering from conditions in most need of research by offering pharmaceutical companies at the forefront of pioneering research, with the latest technological developments.”

For more information about RCLS please contact Randox PR on 028 9442 2413 or email RandoxPR@randox.com


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.